Case Report intROductiOn Posttransplant lymphoproliferative disorders (PTLDs) after kidney transplantation represent the second most common malignancy. The risk of PTLD is 3.9-fold higher than those who are in the waiting list.
Imaging showed normal chest X-ray. Ultrasound sonography of the allograft was normal. His immunosuppression consisted of microemulsion cyclosporine (neoral) 75 mg BD, prednisolone 5 mg and azathioprine 100 mg/day, therapy. The incidence of PTLD is bimodal. There is an increased incidence of 1-year posttransplant following which the incidence declines. It is again increased 7-10 years posttransplant. PTLD shows a high rate of association with EBV infection. Most commonly thought to be from EBV infection of recipient B cells, it may also be of donor origin in some patients. Non-Hodgkin's lymphomas are commonly of B-cell origin. In our patient, the immunohistochemistry showed T-cell non-Hodgkin's lymphoma which has a very guarded prognosis.
The most commonly used pathologic classification of PTLD is the World Health Organization classification, which divides PTLD into three categories as follows: early lesions, polymorphic PTLD, and monomorphic PTLD. We have not checked EBV status either in the donor or the recipient pretransplant. The treatment of PTLD includes reduction and tailoring off immunosuppressive therapy as we did rituximab 375 mg/m 2 once a week for 1 month. As there was no uptake by the allograft on the PET scan, there was no indication to do a graft nephrectomy. Acyclovir and ganciclovir are capable of inhibiting EBV DNA replication. The intensity of immunosuppression rather than the use of specific agents is the main determinant of PTLD. For this reason, reduction (withdrawal) of immunosuppression is the mainstay of therapy. [7] The recovery of the host immune system will elicit the development of a cytotoxic T-lymphocyte against EBV, regaining control on the EBV-driven B-cell proliferation [Flowchart 1]. Mycophenolate mofetil use does not seem to increase the risk of PTLD. [8] Human studies have failed to confirm that mammalian target of rapamycin inhibitors inhibit the development of PTLD. The mortality rate is much greater with PTLD than with lymphomas in the general population. In our patient, who developed PTLD 14 years after successful allografting without prolonged or repeated administration of lymphocyte depleting antibody preparation is intriguing. CMV infection may serendipitously reduce EBV replication and the incidence of PTLD. PTLD may respond to withdrawal or drastic reduction of immunosuppressive therapy. Standard chemotherapy may often be required. Extra-nodal involvement, although common, was not present in our patient. Our patient did not present with severe graft dysfunction and the disease was not localized to the allograft.
cOnclusiOn
A male patient with polymorphic PTLD, 14 years after successful kidney transplantation who presented with Burkholderia cepacia septicemia and past EBV infection, was initially treated with appropriate antibiotic therapy and tailored immunosuppressive agents. The immunohistochemistry showed T-cell non-Hodgkin's lymphoma which has a guarded prognosis. The patient died with the recurrence of septicemia.
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